Multidrug-resistance modulators from Stephania japonica

Area of Science:

• Pharmacology
• Natural Products Chemistry
• Cancer Biology

Background:

• Multidrug resistance (MDR) significantly limits the efficacy of chemotherapy in cancer treatment.
• Natural products are a promising source for novel MDR-reversing agents.
• Stephania japonica is a plant with a history of traditional medicinal use.

Purpose of the Study:

• To investigate the multidrug-resistance-reversing potential of Stephania japonica extracts.
• To isolate and identify active compounds responsible for the observed activity.
• To evaluate the efficacy of isolated compounds against doxorubicin resistance in human breast cancer cells.

Main Methods:

• Bioassay-directed fractionation of Stephania japonica alkaloidal extract.
• Isolation and structural elucidation of bisbenzylisoquinoline alkaloids using chromatographic and spectroscopic techniques.
• Bicinchoninic acid assay to assess multidrug-resistance-reversing activity.
• In vitro evaluation of doxorubicin resistance reversal in human breast cancer cells.

Main Results:

• An alkaloidal extract of Stephania japonica exhibited significant multidrug-resistance-reversing activity.
• Two known bisbenzylisoquinoline alkaloids, isotrilobine (1) and trilobine (2), were successfully isolated.
• Isotrilobine (1) demonstrated potent activity in reversing doxorubicin resistance, comparable to the established drug verapamil (3).

Conclusions:

• Stephania japonica is a valuable source of compounds with multidrug-resistance-reversing properties.
• Isotrilobine is a promising natural compound for overcoming doxorubicin resistance in breast cancer.
• Further investigation into isotrilobine's mechanism of action and therapeutic potential is warranted.